Business
Appointment of Chief Financial Officer
Appointment of Chief Financial Officer.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\nFaron Pharmaceuticals Ltd.\n \n(\"Faron\" or the \"Company\")\n \n \nAppointment of Chief Financial Officer\n \nCompany announcement, 8 August 2024 at 2:00 a.m. EDT / 7:00 a.m. BST / 9:00 a.m. EEST\n \nTURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces the appointment of Yrjö Wichmann, Faron's current interim Chief Financial Officer (CFO, int.), as the Company's permanent Chief Financial Officer (CFO).\n \nMr. Wichmann has served as Faron's interim CFO since April 2024, having previously served as the Company's CFO between 2014 and 2019 and as Senior Vice President, Financing & IR 2019 to April 2024. He is an accomplished biotech and financial executive with over 20 years' experience in financing and investment banking. Prior to his roles at Faron, Mr Wichmann held a number of senior positions within the life sciences and biotechnology sector at IP Finland Oy, Biohit Oyj (NASDAQ OMX Helsinki), CapMan Oyj, FibroGen Europe Oyj (NASDAQ) and D. Carnegies & Co AB. He is a member of the Investment Committee at Dasos Timberland Fund I and II and a board member at Nordic Science Investment Oy investment fund. Mr Wichmann holds a Master's in Economics from Helsinki University. \n \n\"Mr. Wichmann has played a pivotal role in the financial turnaround of the Company over the past months. I am very pleased to see his continued dedication to the Company and I am looking forward to working alongside him as we continue to advance bexmarilimab through clinical development in order to bring this very promising therapy to patients as soon as possible, whilst also delivering value to investors\" said Chief Executive Officer of Faron, Dr. Juho Jalkanen.\n \nMr. Wichmann, incoming Chief Financial Officer, said: \"I am thrilled to be appointed as permanent CFO of Faron and deeply honored by the confidence shown to me by the Board. Faron is entering a very exciting phase and I'm looking forward to continuing to participate in the Company's development under Juho's new leadership.\"\n \n \nFor more information please cont...